# MATERNAL HEALTH

DOI: 10.1377/hlthaff.2023.01437 HEALTH AFFAIRS 43, NO. 4 (2024): 496–503 This open access article is distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) license.

Kara Zivin (kzivin@umich.edu), University of Michigan, Veterans Affairs Ann Arbor Healthcare System, and Mathematica, Ann Arbor, Michigan.

Andrea Pangori, University of Michigan.

Xiaosong Zhang, University of Michigan.

**Anca Tilea**, University of Michigan.

**Stephanie V. Hall**, University of Michigan.

**Ashlee Vance**, Henry Ford Health System, Detroit, Michigan.

Vanessa K. Dalton, University of Michigan.

**Amy Schroeder**, University of Michigan.

**Anna Courant**, University of Michigan.

**Karen M. Tabb**, University of Illinois at Urbana-Champaign, Champaign, Illinois.

By Kara Zivin, Andrea Pangori, Xiaosong Zhang, Anca Tilea, Stephanie V. Hall, Ashlee Vance, Vanessa K. Dalton, Amy Schroeder, Anna Courant, and Karen M. Tabb

# Perinatal Mood And Anxiety Disorders Rose Among Privately Insured People, 2008–20

Nationwide, perinatal mood and anxiety disorder (PMAD) diagnoses among privately insured people increased by 93.3 percent from 2008 to 2020, growing faster in 2015–20 than in 2008–14. Most states and demographic subgroups experienced increases, suggesting worsening morbidity in maternal mental health nationwide. PMAD-associated suicidality and psychotherapy rates also increased nationwide from 2008 to 2020. Relative to 2008–14, psychotherapy rates continued to rise in 2015–20, whereas suicidality rates declined.

nique among high-income countries, the US faces a growing maternal health crisis, with negative impacts on birthing people and infants.<sup>1</sup> Stark disparities in ma-

ternal morbidity and mortality, including mental health conditions, stem from social, structural, and policy features of US society.<sup>2</sup> In this study, we found that the prevalence of privately insured birthing people with diagnosed perinatal mood and anxiety disorder (PMAD) rose substantially between 2008 and 2020, with sharper increases after the 2014 implementation of the Affordable Care Act (ACA) (exhibit 1).

Although previous analyses of PMAD diagnoses focused on prevalence,<sup>3,4</sup> this study examined trends in diagnoses at the national and state levels, making state-to-state comparisons. This study also examined contemporaneous PMADassociated trends in suicidality and psychotherapy receipt by state. Given that the ACA expanded mental health care coverage,<sup>5</sup> which potentially affected these outcomes, we examined pre-ACA (2008–14) and post-ACA (2015–20) trends sep-

### EXHIBIT 1





**SOURCE** Authors' analysis of Optum Clinformatics Data Mart claims data for women ages 15–44 who had a live-birth delivery during the period 2008–20 and had continuous enrollment in a single health plan for 12 months before and 12 months after delivery. **NOTE** Additional details are in the technical appendix (see note 8 in text).

# Overall, access to psychotherapy may have stemmed suicidality despite increasing PMAD diagnoses.

arately. The study contributes to the literature by incorporating trends and pre-ACA and post-ACA comparisons.

We used administrative medical claims representing commercially insured people across the US from Optum's deidentified Clinformatics Data Mart Database. To construct state-specific PMAD diagnosis trajectories and determine how PMAD diagnoses changed from the pre-ACA to post-ACA periods, we examined geographic variations by state and year among women with inpatient deliveries resulting in a live birth.

# **Study Data And Methods**

We conducted serial, cross-sectional analyses of women with live-birth deliveries during 2008– 20, using deidentified claims from the Clinformatics Data Mart Database. The database covers commercially insured people across all fifty US states and Washington, D.C. Our cohort included women ages 15–44 with continuous enrollment in a single health plan for twelve months both before and after delivery.

To code deliveries, we employed International Classification of Diseases, Clinical Modification (ICD-9/10-CM), diagnoses and procedures, diagnosis-related groups, and Current Procedural Terminology codes. To identify PMAD diagnoses during the twenty-four months surrounding delivery, we used the Healthcare Cost and Utilization Project algorithm<sup>6.7</sup> (online appendix exhibit A).<sup>8</sup>

We calculated PMAD diagnoses per 10,000 deliveries by state and year from 2008 to 2020, suicidality prevalence (that is, suicidal ideation or self-harm diagnoses), and any psychotherapy use overall and among people with PMAD diagnoses. We calculated PMAD diagnoses by age (15–24, 25–39, and 40–44), race and ethnicity (Asian, Black, Hispanic, White, and other race), and geographic region (Midwest, Northeast, South, and West). We used linear regressions to examine the potential ACA impact on outcomes across states after its 2014 implementation.<sup>9</sup> We included 2014 in the pre-ACA period as a transition year to help ensure that we did not underestimate the potential ACA impact. We generated range plots, grouping pre-ACA and post-ACA years. We used state-specific linear regressions to identify annual outcome changes per 10,000 deliveries with choropleth maps shaded to visualize values over geographical areas.

In our by-year and by-state analyses, we included states that had ten or more cases per year for PMAD and psychotherapy (within PMAD) outcomes. For suicide-related diagnoses outcomes (within PMAD), we included states with one or more cases per year because of the rare occurrence of suicidality.

Our analysis had limitations. We suppressed findings from states with few outcomes. Our study period captured the beginning of the COVID-19 pandemic, a period when the pandemic potentially had its largest impacts on health care use from stringent lockdown policies; PMAD diagnoses, sequelae, and treatment could have varied since then. Our sample included people continuously enrolled in private insurance for twenty-four months, representing a population not generalizable to those publicly insured or experiencing gaps in coverage. Since disproportionate maternal morbidity and mortality burden likely occurs among publicly insured or uninsured people, future studies should include them. The twenty-four-month study period included at least three months before pregnancy, and thus some mood and anxiety diagnosis codes might not reflect PMAD. Analyses excluded nonlive births, yet people undergoing pregnancy loss could experience PMAD. All of these factors could have limited the generalizability and applicability of our findings.

# **Study Results**

In a national cohort of 750,004 commercially insured women with a live birth between 2008 and 2020, 144,037 had a PMAD diagnosis (19.2 percent; data not shown). The total number of perinatal women decreased from a high of 64,842 in 2008 to a low of 52,479 in 2020, a 19.1 percent decrease (data not shown). Concurrently, women with diagnosed PMAD increased from 9,520 in 2008 to 14,890 in 2020, a 56.4 percent increase (data not shown). PMAD prevalence surged from 1,468 per 10,000 deliveries in 2008 to 2,837 per 10,000 deliveries in 2020, for a 93.3 percent increased (exhibit 1). Appendix exhibit B shows increased PMAD diagnoses by state and year; however, the magnitude of change varied across states.8

Perinatal people in all age, race and ethnicity, and geographic categories experienced growth in PMAD diagnoses from the pre-ACA era to the post-ACA era (exhibit 2). Among races and ethnicities, Black people saw the largest increase (55.0 percent, from 1,404 to 2,176 per 10,000 deliveries). The initial prevalence of PMAD diagnoses was highest among the oldest people (ages 40–44), yet the youngest people (ages 15–24) experienced the largest increase in diagnoses (49.6 percent, from 1,913 to 2,861 per 10,000 deliveries).

Exhibit 3 shows that all states except Vermont experienced increasing rates of PMAD diagnoses post-ACA relative to pre-ACA. Vermont had PMAD diagnoses of 3,614 per 10,000 deliveries pre-ACA, which dropped to 2,292 per 10,000 deliveries post-ACA. Rhode Island and Maine had the highest rates of PMAD diagnoses both pre-ACA (2,720 and 2,708 per 10,000 deliveries, respectively) and post-ACA (3,559 and 3,683 per 10,000 deliveries, respectively). California had the lowest PMAD diagnosis rate pre-ACA, at 1,131 per 10,000 deliveries, which increased to 1,716 per 10,000 deliveries post-ACA. Delaware had the second-lowest PMAD diagnosis rate pre-ACA, at 1,324 per 10,000 deliveries, and the largest increase in diagnoses, reaching 2,968 per 10,000 deliveries (a 124 percent increase). The magnitude and direction of change in PMAD diagnoses pre-ACA to post-ACA varied within age and race and ethnicity categories across states (appendix exhibit C).<sup>8</sup>

Exhibit 4 shows the annual rate of change in PMAD diagnoses per 10,000 deliveries during 2008–20, by state. All nonsuppressed states indicated positive change. Mean annual change across all states reached 109 additional PMAD diagnoses per 10,000 deliveries. Iowa exhibited the greatest annual growth, accruing an average increase of 163 PMAD diagnoses per 10,000 deliveries annually. New Mexico reflected the smallest annual growth, at 49 per 10,000 deliveries. In regional stratification (data not shown), the Midwest had the highest average annual change in PMAD diagnoses per 10,000 deliveries, with 121 per 10,000, followed by the South (107), Northeast (104), and West (97).

Exhibit 5 shows that suicidality among perinatal people with PMAD diagnoses increased pre-ACA but decreased post-ACA. Although PMAD diagnoses and suicidality in the overall perinatal population rose during both periods, PMAD diagnoses accelerated post-ACA and grew far more rapidly than suicidality among those with PMAD diagnoses. Suicidality among those with PMAD diagnoses rose from 175 per 10,000 deliveries in

#### EXHIBIT 2

Total diagnoses of perinatal mood and anxiety disorder (PMAD) per 10,000 deliveries in the US among privately insured women, pre-Affordable Care Act (ACA) and post-ACA, by age, race and ethnicity, and geographic region, 2008–20



Characteristics of perinatal people

**SOURCE** Authors' analysis of Optum Clinformatics Data Mart claims data for women ages 15–44 who had a live-birth delivery during the period 2008–20 and had continuous enrollment in a single health plan for 12 months before and 12 months after delivery. **NOTE** Unadjusted PMAD cases per 10,000 live-birth deliveries are presented as the differences between the pre-ACA period (2008–14) and the post-ACA period (2015–20).

#### EXHIBIT 3

Total diagnoses of perinatal mood and anxiety disorder (PMAD) per 10,000 deliveries in the US among privately insured women, pre-Affordable Care Act (ACA) and post-ACA, by state, 2008–20



**SOURCE** Authors' analysis of Optum Clinformatics Data Mart claims data for women ages 15–44 who had a live-birth delivery during the period 2008–20 and had continuous enrollment in a single health plan for 12 months before and 12 months after delivery. **NOTE** Unadjusted PMAD cases per 10,000 live-birth deliveries are presented as the differences between the pre-ACA period (2008–14) and the post-ACA period (2015–20).

2008 to 213 per 10,000 deliveries in 2020 (21.7 percent increase), whereas the overall suicidality rate among perinatal people rose from 28 per 10,000 deliveries in 2008 to 63 per 10,000 deliveries in 2020 (a 125 percent increase) (appendix exhibit D).<sup>8</sup> We observed considerable differences in annual changes in suicidality rates among women diagnosed with PMAD per 10,000 deliveries across states. Louisiana's annual rate of increase was greatest, at 22 per 10,000 deliv-

## EXHIBIT 4





**SOURCE** Authors' analysis of Optum Clinformatics Data Mart claims data for women ages 15–44 who had a live-birth delivery during the period 2008–20 and had continuous enrollment in a single health plan for 12 months before and 12 months after delivery. **NOTES** Changes reflect unadjusted year-to-year differences during the period 2008–20. States with fewer than 10 diagnosed PMAD cases per year are suppressed (designated "Data suppressed"). Additional details are in the technical appendix (see note 8 in text).

eries. Maryland experienced the greatest negative annual rate of change, at –15 per 10,000 deliveries (appendix exhibit E).<sup>8</sup>

Exhibit 6 shows increasing psychotherapy use among perinatal people with PMAD diagnoses during 2015-20, after nonsignificant declines during 2008–14. The use of psychotherapy among those with PMAD diagnoses rose from 4,741 per 10,000 deliveries in 2008 to 5,535 per 10,000 deliveries in 2020, for a 16.7 percent increase. Psychotherapy use among all perinatal people increased from 1,103 per 10,000 deliveries in 2008 to 2,750 per 10,000 deliveries in 2020, for a 149.3 percent increase (appendix exhibit F).8 Oregon had the most pronounced annual increase, at 223 per 10,000 deliveries. Wisconsin exhibited the lowest annual change, at -46 per 10,000 deliveries. The mean annual change for all states reached 59 per 10,000 deliveries (appendix exhibit G).<sup>8</sup>

## Discussion

PMAD diagnoses represented a large, growing contributor to US maternal morbidity and mortality during 2008-20, with substantial increases across states, ages, and races and ethnicities. Upward trends aligned with maternal health improvement efforts. The ACA required insurance plans to cover maternity and preventive services, which likely increased PMAD screening and detection. The ACA also likely captured a vulnerable population with its coverage, increasing the likelihood of PMAD diagnosis among people at elevated risk. Simultaneously, the Bringing Postpartum Depression Out of the Shadows Act of 2017 and subsequent Biden-Harris administration initiatives to address maternal behavioral health provided needed financial resources to mental health services for perinatal people.<sup>10</sup>

These initiatives operated alongside Maternal Mortality Review Committees, which found that one in nine pregnancy-related deaths during



# Diagnoses of suicidality among privately insured women diagnosed with perinatal mood and anxiety disorders (PMAD) per 10,000 deliveries in the US, 2008–20

**SOURCE** Authors' analysis of Optum Clinformatics Data Mart claims data for women ages 15–44 who had a live-birth delivery during the period 2008–20 and had continuous enrollment in a single health plan for 12 months before and 12 months after delivery. **NOTES** Unadjusted prevalence of suicidality is presented as two trend lines superimposed to smooth out the year-to-year fluctuation in the data and illustrate the differences between the pre-Affordable Care Act (ACA) period (2008–14) and the post-ACA period (2015–20). Additional details are in the technical appendix (see note 8 in text).

2008–17 had mental health conditions as the underlying cause, with 100 percent of mental health–related deaths deemed preventable.<sup>11</sup> Documentation of maternal morbidity and mortality burden and committee recommendations may have improved screening, diagnosis practices, and prevention.

Observed changes in PMAD diagnoses may reflect additional phenomena co-occurring with the ACA, including greater illness awareness,<sup>12</sup> diagnostic coding changes (that is, the 2015 transition from ICD-9 to ICD-10),<sup>13</sup> decreased mental illness stigma,<sup>14</sup> sicker populations,<sup>3</sup> and improved care coverage.<sup>5</sup>

Overall, access to psychotherapy may have stemmed suicidality despite increasing PMAD diagnoses. But although more PMAD diagnoses may have led to increased psychotherapy, therapy access depends on provider availability, which varies by geographic region and insurance coverage network.

Moving forward, strategies focused on subpopulations may help reverse increasing PMAD diagnoses through focusing on younger and Black perinatal people.<sup>2</sup> Intersectionality among age, race and ethnicity, and location may exacerbate mental health needs among subpopulations.<sup>3,15,16</sup>

Accurate tracking will remain critical because it may prove difficult to differentiate increased PMAD diagnoses from improved detection versus increased burden. Tracking could address maternal morbidity and mortality undercounting that results from excluding psychiatric causes of death and limiting the postdelivery period. The Centers for Disease Control and Prevention uses the World Health Organization definition of maternal death as "death of a woman while pregnant or within forty-two days of termination of pregnancy," but the definition excludes accidental or incidental causes (including suicide).<sup>17</sup> Yet people with PMAD experience a sustained risk for maternal morbidity and mortality one year postdelivery.<sup>18</sup>

# Conclusion

Observed trends in PMAD diagnoses among privately insured people during 2008–20 and in associated suicidality and psychotherapy use

#### EXHIBIT 6





**SOURCE** Authors' analysis of Optum Clinformatics Data Mart claims data for women ages 15–44 who had a live-birth delivery during the period 2008–20 and had continuous enrollment in a single health plan for 12 months before and 12 months after delivery. **NOTE** Additional details are in the technical appendix (see note 8 in text).

suggest an increasingly rapid worsening of US maternal mental health morbidity. To better inform policy that addresses this crisis, and as public health and policy shift postpandemic,

future studies could assess post-2020 trends among commercially insured, publicly insured, and uninsured people. ■

Research reported in this publication was supported by the National Institute of Mental Health (Grant No. R01 MH120124) and the National Institute on Minority Health and Health Disparities (Grant No. R01 MD014958) of the National Institutes of Health. The authors are solely responsible for the accuracy of the information presented in this article. Any views or opinions expressed in this article are solely those of the authors, and no endorsement of these views or opinions by the authors' institutions is expressed or implied. The data that support the findings of this study are available from Optum's deidentified Clinformatics Data Mart Database. Restrictions apply to the availability of these data, which were used under license for this study and thus are not publicly available. This is an open access article distributed in

accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) license, which permits others to distribute this work provided the original work is properly cited, not altered, and not used for commercial purposes. See https://creativecommons .org/licenses/by-nc-nd/4.0/. To access the authors' disclosures, click on the Details tab of the article online. [Published online March 20, 2024.]

#### NOTES

- Villavicencio JC, McHugh KW, Edmonds BT. Overview of US maternal mortality policy. Clin Ther. 2020;42(3):408–18.
- **2** Howell EA. Reducing disparities in severe maternal morbidity and mortality. Clin Obstet Gynecol. 2018;61(2):387–99.
- **3** McKee K, Admon LK, Winkelman TNA, Muzik M, Hall S, Dalton VK, et al. Perinatal mood and anxiety disorders, serious mental illness, and delivery-related health out-

comes, United States, 2006–2015. BMC Womens Health. 2020;20(1): 150.

- 4 Hernandez ND, Francis S, Allen M, Bellamy E, Sims OT, Oh H, et al. Prevalence and predictors of symptoms of perinatal mood and anxiety disorders among a sample of urban Black women in the South. Matern Child Health J. 2022;26(4):770–7.
- **5** Beronio K, Glied S, Frank R. How the Affordable Care Act and Mental Health Parity and Addiction Equity

Act greatly expand coverage of behavioral health care. J Behav Health Serv Res. 2014;41(4):410–28.

6 Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project (HCUP), User support, Clinical Classifications Software (CCS) for ICD-10-PCS (beta version) [Internet]. Rockville (MD): AHRQ; 2019 Nov [cited 2024 Feb 22]. Available from: https://hcupus.ahrq.gov/toolssoftware/ccs10/ ccs10.jsp

- 7 Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project, User support, Clinical Classifications Software (CCS) for ICD-9-CM [Internet]. Rockville (MD): AHRQ; 2017 Mar [cited 2024 Feb 22]. Available from: https:// hcup-us.ahrq.gov/toolssoftware/ ccs/ccs.jsp
- **8** To access the appendix, click on the Details tab of the article online.
- **9** Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002; 27(4):299–309.
- 10 Burkhard J, Hutchens BF, Belsito JZ. Bringing Postpartum Depression Out of the Shadows Act passes [Internet]. Los Angeles (CA): Policy Center for Maternal Mental Health; 2017 Apr 10 [cited 2024 Feb 2]. Available from: https://www.2020 mom.org/blog/2017/4/10/bringingpostpartum-depression-out-of-the-

shadows-act-passes

- 11 Trost SL, Beauregard JL, Smoots AN, Ko JY, Haight SC, Moore Simas TA, et al. Preventing pregnancy-related mental health deaths: insights from 14 US Maternal Mortality Review Committees, 2008–17. Health Aff (Millwood). 2021;40(10):1551–9.
- 12 Dagher RK, Bruckheim HE, Colpe LJ, Edwards E, White DB. Perinatal depression: challenges and opportunities. J Womens Health (Larchmt). 2021;30(2):154–9.
- 13 Stewart CC, Lu CY, Yoon TK, Coleman KJ, Crawford PM, Lakoma MD, et al. Impact of ICD-10-CM transition on mental health diagnoses recording. EGEMS (Wash DC). 2019;7(1):14.
- 14 McNab S, Fisher J, Honikman S, Muvhu L, Levine R, Chorwe-Sungani G, et al. Comment: silent burden no more: a global call to action to prioritize perinatal mental health. BMC Pregnancy Childbirth. 2022;22(1): 308.

- 15 Silverman ME, Reichenberg A, Savitz DA, Cnattingius S, Lichtenstein P, Hultman CM, et al. The risk factors for postpartum depression: a population-based study. Depress Anxiety. 2017;34(2):178–87.
- **16** Statz M, Bristow M. Addressing perinatal mood and anxiety disorders (PMADs) in rural places: a knowledge infrastructure. Wellbeing Space Soc. 2023;4:100131.
- **17** Hoyert DL, Miniño AM. Maternal mortality in the United States: changes in coding, publication, and data release, 2018. Natl Vital Stat Rep. 2020;69(2):1–18.
- **18** Admon LK, Dalton VK, Kolenic GE, Tilea A, Hall SV, Kozhimannil KB, et al. Comparison of delivery-related, early and late postpartum severe maternal morbidity among individuals with commercial insurance in the US, 2016 to 2017. JAMA Netw Open. 2021;4(12):e2137716.